Design Therapeutics hints at ‘strategic realignment,’ replaces CEO; Karyopharm co-founder leads ATP's Nereid

2023-11-17

高管变更并购IPO

→ Design Therapeutics chairman Pratik Shah has succeeded João Siffert as CEO while teasing a “strategic realignment” that won’t be revealed until early 2024, according to its Q3 report . Design does elaborate on the status of its cash runway, which is projected to keep the lights on “through 2028” as a result of the changes. Shah has chaired the board since 2017 and is connected to two Laura Shawver biotechs as the ex-chairman of Synthorx — purchased by Sanofi — and the current chairman at ARS Pharmaceuticals , which merged with Shawver-led Silverback Therapeutics last year. Siffert took the top spot at Design in October 2020 after resigning as CEO, head of R&D and CMO at Abeona Therapeutics .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构